Table 1.

Complement inhibitors under advanced clinical development in hematologic diseases

AgentTargetDiseasePhase of development
Crovalimab C5 PNH 
Danicopan Factor D PNH 
ACH-5528/ALXN-2050 Factor D PNH 
BCX9930 Factor D PNH 
Iptacopan Factor B PNH 
Sutimlimab C1s CAD 
Pegcetacoplan C3 AIHA
PNH 
2
Early-access program 
Narsoplimab MASP-2 TA-TMA Expanded-access program 
Ravulizumab C5 TA-TMA 
Coversin C5 and LTB4 inhibition TA-TMA 
AgentTargetDiseasePhase of development
Crovalimab C5 PNH 
Danicopan Factor D PNH 
ACH-5528/ALXN-2050 Factor D PNH 
BCX9930 Factor D PNH 
Iptacopan Factor B PNH 
Sutimlimab C1s CAD 
Pegcetacoplan C3 AIHA
PNH 
2
Early-access program 
Narsoplimab MASP-2 TA-TMA Expanded-access program 
Ravulizumab C5 TA-TMA 
Coversin C5 and LTB4 inhibition TA-TMA 

AIHA, autoimmune hemolytic anemia; LTB4, leukotriene B4.

or Create an Account

Close Modal
Close Modal